AG Publishing House

Research Trends in Multidisciplinary Research (Volume-1)

Volume 1
Year: 2025

AG PH Books

Medicinal Chemistry and Drug Discovery: A Review of Recent Advances and Multidisciplinary Approaches

Dr. Jaggi Lal[1*]

[1]*Associate Professor, Department of Chemistry, Sanskriti University, Mathura, U.P.*

Abstract

The goal of the dynamic area of drug development is to find new therapeutic molecules to treat a variety of illnesses. In order to provide patient-centered care, healthcare experts from several disciplines collaborate via the multidisciplinary approach. This article reviews the many studies on the latest developments and interdisciplinary methods in drug discovery and medicinal chemistry. This review highlight that the medicinal chemistry and drug discovery have undergone transformative advancements through multidisciplinary collaborations and technological innovations. BTA-based compounds have shown broad therapeutic potential, including anticancer, antibacterial, and anti-inflammatory properties. The integration of artificial intelligence, machine learning, high-throughput screening, and rational drug design has accelerated drug development. Targeted therapies, gene-based treatments, and nanotechnology-driven drug delivery systems have improved efficacy and patient compliance. Collaborative efforts among chemists, pharmacologists, and clinicians enhance treatment outcomes, minimize toxicity, and address unmet medical needs. This multidisciplinary approach fosters innovation, clinical standardization, and improved healthcare delivery, ultimately leading to more effective, personalized, and patient-centered therapies.

Keywords: Drug Discovery, Medicinal Chemistry, Multidisciplinary Approaches, Artificial Intelligence, Machine Learning, Drug Delivery, Targeted Therapies, Gene-Based Treatments.

[*] ISBN No. - 978-93-49490-34-5

1 Introduction

In recent years, medicinal chemistry has made considerable strides due to the need for new therapeutic molecules to address a wide range of maladies, such as drug-resistant infections, infectious diseases, cancer, and metabolic disorders. Researchers worldwide have been conducting vigorous investigations of novel bioactive compounds, enhancing their structures, and elucidating their mechanisms of action in order to develop more potent and specialised medications [1]. As a consequence of this effort, many structural scaffolds with promising pharmacological profiles as well as heterocyclic molecules—particularly nitrogen-based derivatives—have been designed, synthesised, and evaluated. To tackle pressing problems in drug development, the body of work discussed here employs a multidisciplinary approach that combines biological assessment, computer modelling, and synthetic chemistry [2]. This body of work emphasises how crucial pharmaceutical chemistry is to closing the gap between basic science and medical application. By creating novel chemicals and understanding their molecular interactions, these research pave the way for the creation of next-generation medicines that address both emerging and persistent health condition [3], [4].

A. Medicinal Chemistry

The field of chemistry devoted to creating new medications and enhancing those that already exist is called medicinal chemistry, also referred to as pharmaceutical chemistry. Pharmacology, biology, and chemistry are all combined in this multidisciplinary area. The goal of practitioners' job is to create and create substances that may cure illnesses, control symptoms, and enhance patients' quality of life [5]. In order to produce selective medications with few adverse effects for patients, they optimise the structure and characteristics of molecules to enhance interactions with target molecules and compounds as well as their metabolism, toxicities, and drug delivery dynamics. In order to create something new, medicinal chemistry combines creativity and knowledge in a data-driven science and art form [6], [7].

B. Overview of Drug Discovery

Finding novel therapeutic molecules to treat a range of illnesses is the goal of the complex and constantly changing scientific process known as drug discovery. Prior to clinical trials and, if successful, regulatory approval and commercialisation, a sequence of processes must be completed, including target discovery and validation, lead compound identification, optimisation, and preclinical review [8]. New medication development has been essential to changing medical care and enhancing patient outcomes for a variety of illnesses, including cancer, chronic disorders, and infectious infections [9].

C. Importance of Advances in Drug Discovery

The health and well-being of people are significantly impacted by developments in medication discovery. Life-saving medications, better patient care, and better disease management have all been made possible by the ongoing search for novel strategies and cutting-edge technology in drug discovery [10]. Novel therapies may provide more individualised treatment choices, less side effects, and increased effectiveness by focussing on certain biological pathways or disease causes. Additionally, precision medicine—which customises treatments for each patient according to their particular genetic

composition and illness characteristics—has become possible because to the development of targeted medications [11].

D. Recent advances in drug discovery

- **A.I. & Data Analytics:** Big data, artificial intelligence (AI), and machine learning are being combined by startups to expedite the resolution of complex problems and automate data processing, surpassing the capabilities of conventional data analysis methods. The technology is being used by businesses such as Protai in Israel to create an AI-powered drug discovery platform [12].
- **Patient-centric Trials:** Based on real-world data collected by wearables and apps, businesses are creating solutions that precisely monitor medication safety and effectiveness for each patient.
- **Assay Development:** In order to create novel medications, assay development is essential. For successful, safe, and reasonably priced research, assay technologies are essential. Using patented technology, the Swiss firm Lino Biotech has created assay sensors that display real-time protein binding and analyse chemical interactions in live cells. The assay design manufacturing costs will be decreased by this method [13].
- **Advanced Manufacturing:** In the clinical manufacturing process, physical technology is essential and facilitates the industry's objective of increasing production velocities and reducing costs. Robotics advancements are cutting down on labour expenses and time spent on manual chores, while augmented reality software and technology are speeding up training and research [14].
- **Synthetic Biology:** With the capacity to synthesise cells, scientists can create precise pre-trial models for medications and get a deeper understanding of the relationships between genes and proteins. Drug development can be expedited and safer by manipulating genetics and synthesising protein libraries.
- **Virtual Trials:** A lack of variety in sample sets, patient recruiting, and regulatory compliance are some of the most difficult aspects of conducting clinical trials. Through peripheral technology, telemedicine, and applications, virtual trials can conduct tests remotely, thereby expediting and simplifying the process of assembling a diverse pool of participants.

2 Literature Review

(Amle & Wanare, 2025) [15] Recent advances in medicinal chemistry have led to the discovery of novel therapeutic chemicals that target a range of maladies, such as drug-resistant infections, metabolic disorders, infectious diseases, and cancer. Researchers have focused on the investigation of novel bioactive compounds, the refinement of their molecular composition, and the determination of their mechanisms of action in order to enhance therapeutic efficacy and safety. Important developments include the creation and synthesis of heterocyclic compounds and nitrogen-based derivatives, as well as the use of environmentally benign synthetic methods. The interdisciplinary aspect of the discipline is highlighted by attempts to avoid antibiotic resistance, develop dual-action medications for complex disorders, and enhance drug delivery systems by fusing synthetic chemistry, computational modelling,

and biological assessment. This comprehensive approach may enhance treatment outcomes and address significant problems in current drug research.

(Badgujar et al., 2024) [16] Benzothiazole (BTA) and its derivatives are especially important among the various pharmacological medications and natural components that include heterocyclic compounds. The discipline of medicinal chemistry, which is founded on BTAs, is currently experiencing a surge in excitement, as there are numerous new discoveries and research projects underway. Many BTA-based compounds, in example, have been used extensively in clinical settings as very successful drugs for a variety of illnesses. As anticancer, antibacterial, antifungal, anti-inflammatory, analgesic, anti-HIV, antioxidant, anticonvulsant, antitubercular, antidiabetic, antileishmanial, antihistaminic, antimalarial, and other medicinal agents, this work presents the current developments of BTA-based compounds in medicinal chemistry in a methodical and comprehensive manner. The authors of this review research believe that it is possible to rationally create more effective diagnostic agents, pathologic probes, and BTA-based drugs that are both active and less harmful.

(Khan et al., 2024) [17] A revolution in drug discovery is possible as a result of the intersection of AI. AI does have certain limits, however, and professionals should be mindful of these ethical and data access concerns. Over the last several years, there has been a significant growth in the use of AI approaches for drug discovery applications, such as denovo drug design, virtual screening, and combinatorial QSAR and QSPR. This study aims to provide a broad overview of artificial intelligence-based drug development and related applications. The shortcomings of the conventional approach to drug design were also emphasised. The limitations of AI in this sector are also addressed, along with possible methods and tactics to get over present obstacles. With this poll, we seek to provide a thorough knowledge of AI's potential in drug development.

(Korylchuk et al., 2024) [18] We intend to examine the advantages and disadvantages of a multidisciplinary treatment approach in clinical medicine in this review. Through cooperative problem-solving and evidence-based procedures, it may enhance patient outcomes, maximise resource utilisation, and promote innovation. In order to provide patients with high-quality healthcare, this literature study focused on the interdisciplinary approach in medicine. highlighting the benefits of cooperating among medical practitioners, such as reducing adverse patient outcomes and improving treatment approaches.

(Patel et al., 2024) [19] Pharmacological information, clinical trial outcomes, molecular structures, and other biological and chemical data may all be used to train artificial intelligence systems. Next, these algorithms can be employed to forecast the efficacy, safety, and prospective adverse effects of innovative drug candidates. New developments in the research and development of medicines will result from the increased usage of artificial intelligence in the pharmaceutical sector. The process of developing new drugs might be drastically changed by artificial intelligence's capacity to forecast a compound's characteristics, find novel therapeutic targets, and enhance clinical trials. Researchers can speed up the creation of new medications, improve patient outcomes, and cut down on the time and expense involved in bringing new medications to market by using artificial intelligence. In the process of developing new

drugs, artificial intelligence holds great promise for addressing unmet medical needs and enhancing healthcare.

(Pibiri, 2024) [20] Computational scientists, pharmacologists, and medicinal chemists have worked together to speed up drug development in the heterocyclic area. Researchers are expanding the boundaries of drug design and identifying novel therapeutic targets by utilising interdisciplinary approaches and cutting-edge technologies. This underscores the immense potential of heterocycles to address unmet medical needs and combat complex diseases.

(Premalatha et al., 2023) [21] The study discusses a variety of innovative methods and approaches utilised in drug discovery and design, such as high-throughput screening, rational drug design, and approaches based on artificial intelligence and machine learning. The substantial advancements in targeted therapeutics are also covered, with an emphasis on precision therapies and personalised medicine that provide increased effectiveness and fewer adverse effects. We also examine recent developments in nanotechnology and drug delivery technologies that have improved therapeutic targeting and bioavailability. The goal of this thorough analysis is to shed light on the most exciting advancements in drug discovery, opening up possible directions for the field of medicine.

(Lin et al., 2022) [22] The physicochemical properties of such a scaffold could be adjusted by adjusting its polarity, lipophilicity, and hydrogen bonding, with the aid of practical synthesis routes via established condensation reactions. This would ultimately lead to its widespread use in kinase hinge-binding motifs, fragment-based drug design, and biomolecular mimetics. Most pyridinone derivatives also have a variety of biological actions, from cardiotonic effects to anticancer, antibacterial, anti-inflammatory, and anticoagulant properties. The structural characteristics and structure–activity correlations (SARs) of each drug-like molecule are covered in this study, which focusses on the recent contributions of pyridinone cores to medicinal chemistry. These developments speed up the creation of novel uses for this physiologically enriched scaffold in drug discovery and help to fully comprehend its potential.

3 Conclusion

In conclusion, the field of medicinal chemistry and drug discovery has experienced rapid and transformative advancements, driven by multidisciplinary collaborations and technological innovations. BTA-based compounds have emerged as promising candidates with diverse pharmacological activities, including anticancer, antibacterial, antifungal, anti-inflammatory, and antidiabetic properties, among others. The ability to design more potent, selective, and less toxic therapeutic agents has been greatly enhanced by integrating computational tools, artificial intelligence, and rational drug design strategies. High-throughput screening and machine learning have significantly accelerated the identification and optimization of drug candidates. Furthermore, targeted therapeutics such as monoclonal antibodies, gene therapies, and RNA-based drugs have revolutionized disease treatment, offering personalized and highly effective solutions. The development of nanotechnology-based drug delivery systems has further improved therapeutic precision, enhancing efficacy while minimizing side effects. Delivery systems utilizing nanoparticles tailored for oral, transdermal, and inhalation routes present a promising shift in

improving patient compliance and treatment outcomes. The collaborative efforts among medicinal chemists, pharmacologists, and clinicians underscore the importance of a multidisciplinary approach, promoting clinical standardization, information sharing, and enhanced patient care. These collective advancements reflect the growing potential of modern medicinal chemistry to address complex diseases and improve the quality and accessibility of healthcare worldwide.

References

[1] D. Castagnolo, P. Sarkar, and D. Schulz, "Looking back and moving forward in medicinal chemistry," *Nat. Commun.*, vol. 14, 2023, doi: 10.1038/s41467-023-39949-6.

[2] J. J. Vanden Eynde *et al.*, "Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6," *Molecules*, vol. 25, 2020.

[3] C. A. Dodson, S. E. Flower, and M. Thomas, "A Multidisciplinary Team-Based Classroom Exercise for Small Molecule Drug Discovery," *J. Chem. Educ.*, vol. 100, 2023, doi: 10.1021/acs.jchemed.3c00066.

[4] W. Cui, A. Aouidate, S. Wang, Q. Yu, Y. Li, and S. Yuan, "Discovering Anti-Cancer Drugs via Computational Methods," *Front. Pharmacol.*, vol. 11, no. May, pp. 1–14, 2020, doi: 10.3389/fphar.2020.00733.

[5] B. Yu, X. Lu, and J. Chang, "Multidisciplinary Training for Fostering Next-Generation Medicinal Chemists," *J. Med. Chem.*, vol. 67, 2024, doi: 10.1021/acs.jmedchem.4c02316.

[6] J. Ingham, J.-L. Ruan, and M. A. Coelho, "Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance.," *BJC reports*, vol. 3, no. 1, 2025, doi: 10.1038/s44276-025-00129-2.

[7] R. R. Ramsay and G. Di Giovanni, "Editorial: Structure-based drug design for diagnosis and treatment of neurological diseases," *Front. Pharmacol.*, vol. 8, no. JAN, pp. 1–2, 2017, doi: 10.3389/fphar.2017.00013.

[8] A. R. Sj and N. P. Shetty, "Advances in designing Next-generation drugs from Natural products," pp. 1–21, 2024.

[9] J. S. Shim and J. O. Liu, "Recent advances in drug repositioning for the discovery of new anticancer drugs," *Int. J. Biol. Sci.*, vol. 10, no. 7, 2014, doi: 10.7150/ijbs.9224.

[10] G. Wu *et al., Overview of Recent Strategic Advances in Medicinal Chemistry,* vol. 62. 2019. doi: 10.1021/acs.jmedchem.9b00359.

[11] I. Cacciatore and L. Marinelli, "Microbial Infections and Wound Healing: Medicinal-Chemistry and Technological Based Approaches," *Pharmaceutics*, vol. 16, 2024, doi: 10.3390/pharmaceutics16020168.

[12] V. Gallego, R. Naveiro, C. Roca, D. Ríos Insua, and N. E. Campillo, "AI in drug development: a multidisciplinary perspective," *Mol. Divers.*, vol. 25, 2021, doi: 10.1007/s11030-021-10266-8.

[13] J. Jiménez-Luna, F. Grisoni, N. Weskamp, and G. Schneider, “Artificial intelligence in drug discovery: recent advances and future perspectives,” *Expert Opin. Drug Discov.*, vol. 16, no. 9, 2021, doi: 10.1080/17460441.2021.1909567.

[14] W. Jiang and Z. Zhao, “Trends in research on AI-aided drug discovery from 2009 to 2023: A 15-year bibliometric analysis,” *Intell. Pharm.*, vol. 3, no. 1, 2025, doi: 10.1016/j.ipha.2024.09.001.

[15] G. M. Amle and R. K. Wanare, “Advances in Medicinal Chemistry : Multidisciplinary Approaches to Drug Design, Synthesis, and Evaluation,” *Int. J. Sci. Res. Sci. Technol.*, vol. 12, no. 11, 2025.

[16] N. D. Badgujar *et al.*, “Recent Advances in Medicinal Chemistry with Benzothiazole-Based Compounds: An In-Depth Review,” *J. Chem. Rev.*, vol. 6, no. 2, 2024, doi: 10.48309/jcr.2024.436111.1290.

[17] M. K. Khan *et al.*, “The recent advances in the approach of artificial intelligence (AI) towards drug discovery,” *Front. Chem.*, vol. 12, 2024, doi: 10.3389/fchem.2024.1408740.

[18] N. Korylchuk, V. Pelykh, Y. Nemyrovych, N. Didyk, and S. Martsyniak, “Challenges and Benefits of a Multidisciplinary Approach to Treatment in Clinical Medicine,” *J. Pioneer. Med. Sci.*, vol. 13, no. 3, 2024, doi: 10.61091/jpms202413301.

[19] R. Patel, N. Kumar Verma, S. Singh, and U. Srivastava, “The Promising Applications of Artificial Intelligence in Drug Development and Discovery,” *Int. J. Multidiscip. Res. Sci. Eng. Technol.*, vol. 7, no. 8, 2024, doi: 10.15680/IJMRSET.2024.0708061.

[20] I. Pibiri, “Recent Advances: Heterocycles in Drugs and Drug Discovery,” *Int. J. Mol. Sci.*, vol. 25, 2024, doi: 10.3390/ijms25179503.

[21] A. Premalatha, M. Atul Bora, D. S. Bhoomandla, and A. Kumari Nakkella, “Recent Advances in Drug Discovery: Innovative Approaches and Targeted Therapeutics,” *Eur. Chem. Bull.*, vol. 12, 2023.

[22] S. Lin *et al.*, “Recent Advances of Pyridinone in Medicinal Chemistry,” *Front. Chem.*, vol. 10, 2022, doi: 10.3389/fchem.2022.869860.